San Francisco, CA (PRWEB) July 01, 2013
A new federal lawsuit filed in the United States District Court for the Southern District of Iowa (Case No. three:2013cv00073) alleges that the dialysis drug GranuFlo triggered the plaintiff to endure a heart attack shortly following dialysis therapy, causing a fatal collision.* This case has been added to federal multidistrict litigation No.2428 now pending before Judge Douglas P. Woodlock in Massachusetts, which lists 161 pending instances as component of this litigation.**

Numerous internal memoranda circulated inside Fresenius, the maker of GranuFlo, suggest that Fresenius might have identified of the heart attack threat associated with its merchandise use, even prior to an FDA recall.*** This enhanced danger is linked to elevated bicarbonate levels, a contributing factor in cardiac arrest.***

Since of the hazardous nature of GranuFlo, the FDA has issued a Class I recall of GranuFlo.**** In issuing the recall, the FDA warned buyers that the elevated sodium bicarbonate levels, could contribute to metabolic alkalosis, which is a substantial threat issue associated with low blood stress, hypokalemia, hypoxemia, hypercapnia and cardiac arrhythmia, which, if not appropriately treated, may culminate in cardiopulmonary arrest.**** The FDA concluded by stating that the serious adverse wellness consequences related with GranuFlo could even consist of death.****

Attorney William Audet, whose law firm Audet and Partners, LLP represents several plaintiffs in active lawsuits against Fresenius, is not surprised by the new lawsuit filings. “The complaints being added to the multidistrict litigation echo troubles articulated by men and women with whom we continue to speak on a weekly basis. These problems frequently involve heart attacks or cardiac arrest occurring inside hours following dialysis treatment options involving the administration of GranuFlo. The evidence emerging by way of discovery suggests that Fresenius may possibly have failed to act in a responsible style upon becoming conscious of this potential heart attack hyperlink a number of years ago.”

If you or somebody you know has suffered an injury that might be connected to GranuFlo, please get in touch with Audet & Partners, LLP by calling us toll cost-free at 800.965.1461. For extra data, you can visit our informational internet site at http://www.granuflodialysisrisk.com. 

U.S. District Court for the Southern District of Iowa, Case No. 3:2013cv00073
** United States Judicial Panel on Multidistrict Litigation, May 14, 2013 http://www.jpml.uscourts.gov/websites/jpml/files/Pending%20MDL%20Dockets_By%20District_Could-14-2013.pdf

*** New York Times, June 15, 2012 http://www.nytimes.com/2012/06/15/wellness/fda-investigates-fresenius-for-failure-to-warn-of-risk.html

**** FDA, May 25, 2012 http://www.fda.gov/Security/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm305630.htm





Far more Administrator Press Releases